Cargando…

An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins....

Descripción completa

Detalles Bibliográficos
Autores principales: J Gingell, Joseph, Simms, John, Barwell, James, Poyner, David R, Watkins, Harriet A, Pioszak, Augen A, Sexton, Patrick M, Hay, Debbie L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869360/
https://www.ncbi.nlm.nih.gov/pubmed/27462459
http://dx.doi.org/10.1038/celldisc.2016.12
_version_ 1782432305643520000
author J Gingell, Joseph
Simms, John
Barwell, James
Poyner, David R
Watkins, Harriet A
Pioszak, Augen A
Sexton, Patrick M
Hay, Debbie L
author_facet J Gingell, Joseph
Simms, John
Barwell, James
Poyner, David R
Watkins, Harriet A
Pioszak, Augen A
Sexton, Patrick M
Hay, Debbie L
author_sort J Gingell, Joseph
collection PubMed
description G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein–protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.
format Online
Article
Text
id pubmed-4869360
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48693602016-07-26 An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology J Gingell, Joseph Simms, John Barwell, James Poyner, David R Watkins, Harriet A Pioszak, Augen A Sexton, Patrick M Hay, Debbie L Cell Discov Article G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein–protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class. Nature Publishing Group 2016-05-17 /pmc/articles/PMC4869360/ /pubmed/27462459 http://dx.doi.org/10.1038/celldisc.2016.12 Text en Copyright © 2016 SIBS, CAS http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
J Gingell, Joseph
Simms, John
Barwell, James
Poyner, David R
Watkins, Harriet A
Pioszak, Augen A
Sexton, Patrick M
Hay, Debbie L
An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title_full An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title_fullStr An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title_full_unstemmed An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title_short An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
title_sort allosteric role for receptor activity-modifying proteins in defining gpcr pharmacology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869360/
https://www.ncbi.nlm.nih.gov/pubmed/27462459
http://dx.doi.org/10.1038/celldisc.2016.12
work_keys_str_mv AT jgingelljoseph anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT simmsjohn anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT barwelljames anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT poynerdavidr anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT watkinsharrieta anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT pioszakaugena anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT sextonpatrickm anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT haydebbiel anallostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT jgingelljoseph allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT simmsjohn allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT barwelljames allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT poynerdavidr allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT watkinsharrieta allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT pioszakaugena allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT sextonpatrickm allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology
AT haydebbiel allostericroleforreceptoractivitymodifyingproteinsindefininggpcrpharmacology